ReviewToxicological sciences : an official journal of the Society of Toxicology2018
The Evolution of Carcinogenesis.
Review in Toxicological sciences : an official journal of the Society of Toxicology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Bioactivity ofPlants (Basel, Switzerland) · 2026Article
- Extraction of pH-Dependent DNA-Binding Anti-Tumoral Peptides fromPharmaceuticals (Basel, Switzerland) · 2026Article
- Antitumor effects of Dadas Cress (Lepidium sativum var. sativum) on Ehrlich Ascites tumor cells: an in vitro and in vivo study.Journal of molecular histology · 2025Article
- Epigenetic agents, zebularine and valproic acid, inhibit the growth of the oral squamous cell carcinoma cell line HSC4 in vitro and in vivo.Discover oncology · 2025Article
- Screening and validating the optimal panel of housekeeping genes for 4T1 breast carcinoma and metastasis studies in mice.Scientific reports · 2024Article
- The Lawson-loaded β-cyclodextrin nanocarriers (LB-NCs) a novel targeted cancer cell in stomach and breast cancer as a drug delivery system.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- The silibinin-loaded Zein-β cyclodextrin nano-carriers (SZBC-NCs) as a novel selective cancer cell drug delivery system in HT-29 cell line.Scientific reports · 2024Article
- Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets.Molecules (Basel, Switzerland) · 2024Review
- Novel Anti-tumor Strategy for Breast Cancer: Synergistic Role of Oleuropein with Paclitaxel Therapeutic in MCF-7 Cells.Anti-cancer agents in medicinal chemistry · 2024Article
- Understanding the role of nerves in head and neck cancers - a review.Oncology reviews · 2024Review
- Review
- Realistic aspects behind the application of the rat model of chemically-induced mammary cancer: Practical guidelines to obtain the best results.Veterinary world · 2023Review
- The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives.Molecules (Basel, Switzerland) · 2023Review
- Electrochemical and Optical Sensors for the Detection of Chemical Carcinogens Causing Leukemia.Sensors (Basel, Switzerland) · 2023Review
- Codelivery of Phytochemicals with Conventional Anticancer Drugs in Form of Nanocarriers.Pharmaceutics · 2023Review
- Review
- Tumor abnormal protein as a promising biomarker for screening solid malignancies and monitoring recurrence and metastasis.Frontiers in oncology · 2023Article
- The Role of Selected Serpins in Gastrointestinal (GI) Malignancies.Journal of clinical medicine · 2022Review
- Regulation ofInternational journal of molecular sciences · 2022Article
- Solid Tumors and Kinase Inhibition: Management and Therapy Efficacy Evolution.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.